title: Antiphospholipid antibodies. Risk assessments for solid organ, bone marrow, and tissue transplantation.
abstract: The literature pertaining to transplantation of solid organs, bone marrow, and other tissues in aPL-positive patients has been reviewed. The effects that aPL have relative to BMT are altogether different than those ascribed to solid organs and tissues. By definition, the transplantation of allogeneic bone marrow serves to reconstitute the recipient with a completely new and genetically different repertoire of antibody-producing cells. Previously aPL-positive bone marrow recipients become aPL-negative subsequent to transplantation assuming that the marrow donor is aPL-negative. These observations are the basis for contemporary experimental approaches to curing certain autoimmune diseases with BMT. Similarly, it would follow that an aPL-negative patient provided cells from an aPL-positive donor could become aPL-positive and suffer increased risk for thrombosis. From the data provided in most of the non-bone marrow publications, the presence of aPL should be considered a grave risk factor for any potential solid organ or tissue transplant candidate. Peritoneal dialysis patients seem to be at maximal risk. Given the serious emotional and economic impact of irreversible thrombotic loss suffered by organ transplant recipients, these factors alone should justify the modest expense of pretransplant aPL screening. In the United States, the average cost of losing a kidney transplant to aPL-associated thrombosis was estimated from 1996 data to be $82,000. The cost of losing a heart or liver is measured not only in dollars but often in the patient's life. The encouraging news, however, is that once aPL are identified before transplantation, prophylactic anticoagulation seems to be capable of forestalling untoward aPL-associated allograft events. Clearly, much remains to be discovered in exploring the pathobiologic characteristics of aPL in the laboratory as well as in neutralizing their procoagulant effects at the bedside.
authors.affiliation: HLA-Vascular Biology Laboratory, St. Francis Hospital and Health Center, Indiana, USA. jmcintyre@iquest.net
authors.forename: J A
authors.initials: JA
authors.lastname: McIntyre
authors.forename: D R
authors.initials: DR
authors.lastname: Wagenknecht
mesh_terms: D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D017209:Apoptosis; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology*; D004195:Disease Models, Animal; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D051379:Mice; D016377:Organ Transplantation / Q000009:adverse effects*; D018570:Risk Assessment; D016378:Tissue Transplantation / Q000009:adverse effects*
chemical_list: D017152:Antibodies, Antiphospholipid